20May, 2025 CereVasc Announces Journal of Molecular Therapy Publication Highlighting the eShunt® Platform as a CNS Gene Therapy Delivery MethodCarlos Bonilla2025-05-22T23:13:55+00:00May 20th, 2025|Press Release|Read More
25Feb, 2025 CereVasc Announces First Patient Randomized to eShunt® System Treatment in STRIDE Pivotal TrialCarlos Bonilla2025-05-23T17:30:36+00:00February 25th, 2025|Press Release|Read More
13Feb, 2025 CereVasc Receives Approval for STRIDE Clinical Trial of the eShunt® System for the Treatment of Elderly Patients with Normal Pressure Hydrocephalus in ArgentinaCarlos Bonilla2025-05-22T23:15:02+00:00February 13th, 2025|Press Release|Read More
05Feb, 2025 CereVasc, Inc. Announces Results of Groundbreaking Clinical Study of the eShunt® System in the Treatment of Elderly Patients with Normal Pressure HydrocephalusCarlos Bonilla2025-05-22T23:12:13+00:00February 5th, 2025|Press Release|Read More
14Jan, 2025 CereVasc Announces First Enrollment in STRIDE Clinical Trial of the eShunt® System for Normal Pressure HydrocephalusCarlos Bonilla2025-05-22T23:16:42+00:00January 14th, 2025|Press Release|Read More
25Nov, 2024 CereVasc to Present at the Piper Sandler 36th Annual Healthcare ConferenceCarlos Bonilla2025-05-20T21:01:09+00:00November 25th, 2024|Press Release|Read More
17Sep, 2024 CereVasc Announces Enrollment of the 50th Patient in Pilot Studies of the eShunt® System for Normal Pressure Hydrocephaluscerevasc2024-10-14T16:19:05+00:00September 17th, 2024|Press Release|Read More
28Aug, 2024 CereVasc, Inc. Receives FDA Breakthrough Device Designation for the eShunt® System for Use in Pediatric Patientscerevasc2025-05-22T23:18:23+00:00August 28th, 2024|Press Release|Read More
16Jul, 2024 CereVasc Announces Appointments of New DirectorsAdmin2024-07-18T18:46:24+00:00July 16th, 2024|Press Release|Read More
13May, 2024 CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure HydrocephalusAdmin2024-05-28T21:41:18+00:00May 13th, 2024|Press Release|Read More
